Kura Oncology Inc (NASDAQ:KURA) — Market Cap & Net Worth
Market Cap & Net Worth: Kura Oncology Inc (KURA)
Kura Oncology Inc (NASDAQ:KURA) has a market capitalization of $799.86 Million ($799.86 Million) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9741 globally and #2658 in its home market, demonstrating a -13.78% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kura Oncology Inc's stock price $9.01 by its total outstanding shares 88774365 (88.77 Million). See how much does Kura Oncology Inc reinvest in capital to understand how much of operating cash flow is reinvested back into capital assets.
Kura Oncology Inc Market Cap History: 2015 to 2026
Kura Oncology Inc's market capitalization history from 2015 to 2026. Data shows change from $745.70 Million to $799.86 Million (-4.00% CAGR).
Index Memberships
Kura Oncology Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.03% | #277 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #1024 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.05% | #165 of 263 |
Weight: Kura Oncology Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kura Oncology Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kura Oncology Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
13.67x
Kura Oncology Inc's market cap is 13.67 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $773.22 Million | $53.88 Million | -$173.98 Million | 14.35x | N/A |
| 2025 | $922.37 Million | $67.48 Million | -$278.67 Million | 13.67x | N/A |
Competitor Companies of KURA by Market Capitalization
Companies near Kura Oncology Inc in the global market cap rankings as of August 1, 2026.
Key companies related to Kura Oncology Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Kura Oncology Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Kura Oncology Inc's market cap moved from $745.70 Million to $ 799.86 Million, with a yearly change of -4.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $799.86 Million | -13.28% |
| 2025 | $922.37 Million | +19.29% |
| 2024 | $773.22 Million | -39.43% |
| 2023 | $1.28 Billion | +15.87% |
| 2022 | $1.10 Billion | -11.36% |
| 2021 | $1.24 Billion | -57.13% |
| 2020 | $2.90 Billion | +137.53% |
| 2019 | $1.22 Billion | -2.07% |
| 2018 | $1.25 Billion | -8.24% |
| 2017 | $1.36 Billion | +159.32% |
| 2016 | $523.77 Million | -29.76% |
| 2015 | $745.70 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Kura Oncology Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $799.86 Million USD |
| MoneyControl | $799.86 Million USD |
| MarketWatch | $799.86 Million USD |
| marketcap.company | $799.86 Million USD |
| Reuters | $799.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapi… Read more